Eli Lilly (LLY) Director Ralph Alvarez Receives Award of 10.659 Shares

What Happened

• Ralph Alvarez, a director of Eli Lilly & Co. (LLY), was granted 10.659 shares (transaction code A) on 2026-09-21. The grant is reported at $1,164.89 per share, for a total value of approximately $12,417. This was an award of deferred compensation rather than an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-09-21; 10.659 shares @ $1,164.89 each (total ≈ $12,417).
• Filing date: 2026-09-22 (timely filing, one day after transaction).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: (1) The shares were elected to be deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock after the reporting person's separation from service. (2) The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
• Transaction type: Award/grant of deferred stock units (not a purchase or sale).

Context

• This is director compensation deferred into stock units — a routine form of non-employee director pay and not a direct market purchase or sale that typically signals a trading view.
• Because the units are deferred and will convert to shares upon separation, they reflect compensation timing choices, not an immediate transfer of market risk (no immediate cashless sale or exercise involved).